Our Portfolio
Sweeping structural changes and scientific breakthroughs are
driving demand for new products, services and technologies
Athersys, Inc. (NASDAQ:ATHX) is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including ischemic stroke, myocardial infarction, acute respiratory distress syndrome, bone marrow transplantation/oncology support and other indications. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders.
EndoGastric Solutions, Inc. is the leading medical device company in the minimally invasive treatment of gastroesophageal reflux disease, commonly known as GERD. EGS has pioneered the Transoral Incisonless Fundoplication ("TIF") procedure, which is a surgical procedure performed on a patient through the mouth and esophagus and without incisions to durably repair and reconstruct the gastroesophageal valve.
Management Health Solutions, Inc. is a full service supply chain management company specializing in physical inventory measurement, data management, and supply chain optimization services for hospitals. The Company utilizes state-of-the-art technology to create greater visibility for the clinical supplies that are purchased, used, and stored and thereby improve health care quality while reducing clinical supply costs.
ActiveHealth Management, Inc. was acquired by Aetna Inc. in May 2005. Prior to the acquisition, ActiveHealth Management was a healthcare information technology and services company focused on improving the effectiveness of disease diagnosis and management. Key to the company's capabilities was proprietary software that integrated a wide array of clinical information with protocols and standards to elevate the quality of care in real time and reduce the overall cost for payors.
Aethon, Inc. was acquired by Singapore Technologies Ltd (ST Engineering) in July 2017. Prior the acquisition, Aethon was the leading independent maker of practical, dependable courier robots for hospitals. The company’s proprietary, fully autonomous robots improve efficiency of hospital deliveries such as clinical supplies, pharmaceuticals, food, linen, waste and other items.
Ambit Biosciences Corp. was acquired by Daiichi Sankyo (TYO: 4568) in November of 2014. Prior to the acquisition, the company was focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers of those diseases. Ambit’s lead drug candidate, Quizartinib, is a once-daily, orally-administered kinase inhibitor initially targeting patients with relapsed/refractory acute myeloid leukemia, or AML. Ambit completed an IPO in May 2013.
AMICAS, Inc. was acquired by VitalWorks, Inc. in November 2003. Prior to the acquisition, the company was engaged in the development and marketing of web-based Picture Archiving and Communication Systems "PACS" that provide diagnostic quality radiology image management services, including secure image capture, distribution, workflow integration and image archiving.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotechnology company developing small-molecule, orally-active drugs, known as Pharmacological Chaperones for treating human genetic disorders. Pharmacological chaperones are designed to help mutant proteins fold correctly into their normal 3-dimensional conformations, rescuing intrinsic biological activity and function. Amicus completed an IPO in May 2007.
BEI Medical Systems Company, Inc. was acquired by Boston Scientific Corporation in June 2002. Prior to the acquisition, the company was engaged in the manufacture and marketing of a new, proprietary and minimally invasive endometrial ablation system, the Hydro ThermAblator HTA), representing a major advance in the treatment of abnormal uterine bleeding, a condition known as menorrhagia, that affects more than 10 million women in the U.S. annually. The HTA system received FDA approval and was commercially launched in 2001.
Bio-Lok International, Inc. was acquired by Healthpoint Capital in October 2006. Prior to the acquisition, the company was engaged in the manufacturing and distribution of an innovative line of dental implants and other products targeting the global oral surgery and general dentistry markets. Bio-Lok's industry-leading and FDA approved dental implant system, the Silhouette Laser-Lok™, utilizes a proprietary, laser micro-machined surface the Bio-Affinity Collar) to promote soft tissue and bone adherence while preventing epithelial down-growth - major advancements in the field of esthetic dentistry.
BioStorage Technologies, Inc. was acquired by Brooks Automation in December 2015. Prior to the acquisition, the company was a leading provider of advanced biomaterials storage, inventory management and worldwide cold-chain logistics. The company served pharmaceutical developers and manufacturers, non-profit and corporate clinical research facilities, donor organizations, forensic laboratories, universities, zoological and veterinarian treatment and research facilities, healthcare and life sciences companies.
Clinical Micro Sensors, Inc. was acquired by Motorola in June 2000. Prior to the acquisition, the company was engaged in the development of DNA biochips aimed at enabling the delivery of valuable genetic information to biomedical researchers, physicians, and industrial users.
Conor Medsystems, Inc. was acquired by Johnson & Johnson in January 2007. Prior to the acquisition, Conor was developing, manufacturing and marketing next generation drug eluting stents. The company's initial focus was on the treatment of coronary restenosis. Conor completed an IPO in December 2004.
Corus Pharma, Inc. was acquired by Gilead Sciences in August 2006. Prior to the acquisition, Corus was developing small molecule drugs for the treatment of respiratory diseases.
Health Language, Inc. was acquired by Wolters Kluwer in January 2013. Health Language provides software for managing and updating standard and localized healthcare terminology. The Company also offers clinical content and professional services to enable interoperability, ICD-10 conversion, web-based terminology mapping, and Meaningful Use compliance.
Healthsense Inc. was acquired by Greatcall, Inc. in December 2016. Prior to the acquisition, Healthsense was a leading remote monitoring company focused on aging-in-place solutions for the elderly. The flagship Healthsense product is the eNeighbor® system, which monitors individuals in their homes and automatically calls for help if it detects a possible problem. The eNeighbor® system utilizes a series of wireless sensors placed throughout the residence that capture the occupant's activities of daily living.
Heartscape Technologies, Inc. was acquired by Roper Industries, Inc. pursuant to an asset transaction in February 2010. Prior to the acquisition, the company was engaged in the manufacture, design and commercialization of the Prime ECG System, an 80-lead ECG developed for accurate early detection of heart attack and ischemia in the emergency room setting.
Medingo Ltd. was acquired by F. Hoffman La-Roche in 2010. Prior to the acquisition, Medingo was developing next generation insulin dispensing and glucose monitoring technologies for patients with diabetes. Medingo’s initial product, The Solo™, is one of the first products in a new category of insulin pumps called "dispensing patches" that will address the shortcomings of traditional larger "pager-like" pumps.
NuGEN Technologies, Inc. was acquired by The Tecan Group in August 2018. Prior to the acquisition, NuGEN was a leading life sciences research tools company developing and marketing powerful technology for efficient and cost-effective sample preparation and amplification of nucleic acids (DNA and RNA), a critical rate limiting step in genomics research for the identification of new drugs and drug targets.
Tabula Rasa Healthcare, Inc. (NASDAQ: TRHC) is a personalized medication therapy management and pharmacy services company that achieves superior outcomes by leveraging its proprietary technology platform to reduce medication risk for chronically ill populations. Its platform is proven to increase medication adherence and reduce hospitalization for high-risk elderly patients. Tabula Rasa Healthcare accomplishes this through a patented electronic medication system, real-time involvement of geriatric pharmacists and customized adherence packaging. Tabula Rasa completed its IPO in September 2016.
Tactile Systems Technology Inc. (NASDAQ: TCMD) is a market leading medical device company dedicated to advancing the standard of care for at–home treatment of lymphedema, chronic edema, and non–healing venous ulcers. Tactile’s Flexitouch system is an innovative, patented medical device that simulates the gold-standard Manual Lymphatic Massage in cycle speed and pressure levels and effectively brings clinic based treatment into the patient’ home. Tactile completed its IPO in July 2016.
U-Systems, Inc. was acquired by GE Healthcare in October 2012. Prior to the acquisition, U-Systems designed, developed, manufactured and marketed innovative, ultrasound systems and software to assist the radiologist in detection of breast cancer in women with dense breast tissue. The Company's first product, the Somo.v™ automatically scans the whole-breast and presents the results to the physician in a mammogram-like format - enabling high volume, cost-effective ultrasound imaging.